Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: BMS looks to new launches amid patent losses; Novartis prioritizes high-value medicines and the US market; Biogen learns from Aduhelm experience; J&J builds myeloma franchise; and Asian bioventures debate best strategies.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 28 October 2022, including: Bristol Myers Squibb Company looks to new launches amid patent losses; Novartis AG prioritizes high-value medicines and the US market; Biogen, Inc. learns from Aduhelm experience; Johnson & Johnson builds myeloma franchise; and Asian bioventures debate best strategies.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "All Eyes On Bristol's New Launches" - Scrip, 26 Oct, 2022.)
(Also see "Weak Spots Blight Novartis Third Quarter As New Products Shine" - Scrip, 25 Oct, 2022.)
(Also see "Biogen Weighs Aduhelm Lessons Ahead Of Lecanemab Launch" - Scrip, 25 Oct, 2022.)
(Also see "J&J Adds Second Anti-BCMA Myeloma Therapy In US With Tecvayli Approval" - Scrip, 26 Oct, 2022.)
(Also see "How Do Bioventures Thrive In APAC? Strategies And Risks Beyond Borders" - Scrip, 24 Oct, 2022.)